AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.110

-0.080-3.65%

Volume:3.28M

Turnover:6.89M

Market Cap:2.72B

PE:-19.74

High:2.170

Open:2.170

Low:2.080

Close:2.190

52wk High:3.310

52wk Low:1.515

Shares:1.29B

Float Shares:786.49M

Volume Ratio:0.91

T/O Rate:0.42%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.107

EPS(LYR):-0.123

ROE:-18.22%

ROA:-6.16%

PB:3.26

PE(LYR):-17.18

Loading ...

Overview Company News Filings

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

THOMSON REUTERS

Mesoblast Ltd - Qtr Revenue From Cell Therapy Products US$20.6 Mln

THOMSON REUTERS

Mesoblast (ASX:MSB) J-Code for Ryoncil Secures Reimbursement Access Is the Commercial Strategy Evolving?

Simply Wall St.

Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says

MT Newswires Live

Mesoblast (ASX:MSB) Valuation in Focus After Ryoncil Secures U.S. Reimbursement Milestone

Simply Wall St.

BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues

Stock Track | Mesoblast Soars 5.24% as Piper Sandler Boosts Target Price by 46%

Stock Track | Mesoblast Shares Soar 5.24% After Piper Sandler Boosts Target Price to $35

Mesoblast Ltd : Piper Sandler Raises Target Price to $35 From $24

THOMSON REUTERS

BUZZ-ASX-listed Mesoblast jumps on key drug's quarterly sales surge

BRIEF-Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

THOMSON REUTERS

Stock Track | Mesoblast Soars 11.20% as Ryoncil Sales Drive $21.9 Million Quarterly Revenue

Stock Track | Mesoblast Soars 11.20% as Quarterly Ryoncil Sales Generate $21.9 Million Revenue

Mesoblast Ltd - Gross Revenue of $21.9 Mln on Ryoncil Sales for Quarter

THOMSON REUTERS

Why Mesoblast (ASX:MSB) Is Up 15.0% After Securing US Medicare J-Code for Ryoncil

Simply Wall St.

Mesoblast (ASX:MSB): Assessing Valuation After Ryoncil Wins Permanent U.S. J-Code for Reimbursement

Simply Wall St.

Weekly Wrap: Will the ASX 200 Break Records? Investors Hope for Continued Momentum

Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Secures US Medicare Billing Approval

Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Receives US Medicare Billing Approval

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.11,"timestamp":1774588320000,"preClose":2.19,"halted":0,"volume":3276490,"delay":0,"changeRate":-0.036529680365296836,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.10687726942628903,"marketStatus":"Market Closed","change":-0.08,"latestTime":"03-27 16:12:00 AEDT","open":2.17,"high":2.17,"low":2.08,"amount":6893585,"amplitude":0.041096,"askPrice":2.12,"askSize":15347,"bidPrice":2.09,"bidSize":73368,"shortable":3,"etf":0,"ttmEps":-0.10687726942628903,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.19,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.9114152317141351,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.19,"auctionPrice":2.11,"auctionVolume":709695,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588215608}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.122831,"volumeRatio":0.9114152317141351,"shares":1290302187,"dividePrice":0,"high":2.17,"amplitude":0.041096,"preClose":2.19,"low":2.08,"week52Low":1.515,"pbRate":"3.26","psRate":"28.67","week52High":3.31,"institutionHeld":0,"latestPrice":2.11,"committee":0.654016,"eps":-0.10687726942628903,"divideRate":0,"volume":3276490,"delay":0,"ttmEps":-0.10687726942628903,"open":2.17,"prevYearClose":2.72,"prevWeekClose":2.06,"prevMonthClose":2.24,"prevQuarterClose":2.72,"fiveDayClose":2.06,"twentyDayClose":2.24,"sixtyDayClose":2.72,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576860002","title":"Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2576860002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576860002?lang=en_us&edition=fundamental","pubTime":"2025-10-20 07:48","pubTimestamp":1760917708,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nTUA6R4H2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2576001908","title":"Mesoblast Ltd - Qtr Revenue From Cell Therapy Products US$20.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2576001908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576001908?lang=en_us&edition=fundamental","pubTime":"2025-10-20 06:47","pubTimestamp":1760914029,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nTUE4HBZV9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7508","BK7501","BK7067","MSB.AU","BK4139"],"gpt_icon":0},{"id":"2575735865","title":"Mesoblast (ASX:MSB) J-Code for Ryoncil Secures Reimbursement Access Is the Commercial Strategy Evolving?","url":"https://stock-news.laohu8.com/highlight/detail?id=2575735865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575735865?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:27","pubTimestamp":1760527671,"startTime":"0","endTime":"0","summary":"On October 1, 2025, Mesoblast Limited announced that a permanent Medicare HCPCS J-Code (J3402) for Ryoncil® (remestemcel-L-rknd) became active, providing a standardized billing pathway for this FDA-approved therapy in pediatric steroid-refractory acute graft-versus-host disease.\nThis CMS formal recognition is expected to simplify reimbursement and potentially broaden both public and private payer access to the only mesenchymal stromal cell product approved for children under age 12 with this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-j-code-for-ryoncil-secures-reimbursement-ac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-j-code-for-ryoncil-secures-reimbursement-ac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","MSB.AU","BK7067","MSB","BK7508","BK4006"],"gpt_icon":0},{"id":"2575276394","title":"Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2575276394","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575276394?lang=en_us&edition=fundamental","pubTime":"2025-10-13 14:51","pubTimestamp":1760338274,"startTime":"0","endTime":"0","summary":"Mesoblast's  quarterly revenue suggests that around 113 paid infusions were given during the September quarter, and analysts now forecast 63 patients will complete treatments in fiscal year 2026, or 17% of total US patients per annum, according to a Monday note by Jefferies.Ryoncil is a bone marrow-derived mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients, two months of age and older.The firm reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, compared with the analysts' estimate of net revenue at $18.7 million.The investment firm recommended a hold rating on Mesoblast and lifted the price target to AU$3 per share from AU$2.70 per share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK4139","BK7067","BK7508","MESO","MSB.AU"],"gpt_icon":0},{"id":"2574307496","title":"Mesoblast (ASX:MSB) Valuation in Focus After Ryoncil Secures U.S. Reimbursement Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2574307496","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574307496?lang=en_us&edition=fundamental","pubTime":"2025-10-12 09:24","pubTimestamp":1760232243,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) shares have drawn attention after the company announced that its Ryoncil therapy received a permanent J-Code from U.S. Centers for Medicare & Medicaid Services, effective October 1. This update simplifies reimbursement and billing for providers.\nSee our latest analysis for Mesoblast.\nMesoblast’s latest breakthrough with Ryoncil arrives as investor optimism has been building steadily. After lagging earlier in the year, the share price has surged 75% in the past three...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-ryoncil-secures-us","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-ryoncil-secures-us","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7508","MSB","DCF","BK7501","MSB.AU","BK7067"],"gpt_icon":0},{"id":"2574189956","title":"BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2574189956","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574189956?lang=en_us&edition=fundamental","pubTime":"2025-10-09 12:04","pubTimestamp":1759982659,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues** Shares of inflammatory disease drug maker Mesoblast MSB.AX rise as much as 5.1% to A$3.07, their highest level since February 10** Bell Potter lifts FY26 revenue forecast 38% to A$108 mln  after drug Ryoncil's Sept quarter gross revenue of A$21.5 mln beat estimates** Brokerage expects Ryoncil revenues to rise each quarter, sees Sept quarter net revenue at A$19.1 mln** Expects positive 1H26 EBITDA and equity-based remuneration, operating cash surplus likely by 4Q26** Stock down 3.2% YTD, including the session's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nL6N3VQ05W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","MSB.AU","BK7067"],"gpt_icon":0},{"id":"1178202334","title":"Stock Track | Mesoblast Soars 5.24% as Piper Sandler Boosts Target Price by 46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178202334","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178202334?lang=en_us&edition=fundamental","pubTime":"2025-10-08 07:04","pubTimestamp":1759878256,"startTime":"0","endTime":"0","summary":"Shares of Mesoblast Ltd (MSB.AU) are soaring in the intraday trading session, jumping 5.24% following a significant target price upgrade from Piper Sandler. The surge comes as investors react...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1106846125","title":"Stock Track | Mesoblast Shares Soar 5.24% After Piper Sandler Boosts Target Price to $35","url":"https://stock-news.laohu8.com/highlight/detail?id=1106846125","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106846125?lang=en_us&edition=fundamental","pubTime":"2025-10-08 07:04","pubTimestamp":1759878255,"startTime":"0","endTime":"0","summary":"Shares of Mesoblast Ltd (MSB.AU) are soaring in Wednesday's intraday trading, climbing 5.24% following a bullish analyst update. The surge comes after Piper Sandler, a prominent investment bank,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"2573968543","title":"Mesoblast Ltd : Piper Sandler Raises Target Price to $35 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2573968543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573968543?lang=en_us&edition=fundamental","pubTime":"2025-10-07 21:12","pubTimestamp":1759842746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MESO","BK7508","BK4139","BK7501","MSB.AU"],"gpt_icon":0},{"id":"2573070938","title":"BUZZ-ASX-listed Mesoblast jumps on key drug's quarterly sales surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2573070938","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573070938?lang=en_us&edition=fundamental","pubTime":"2025-10-07 10:09","pubTimestamp":1759802984,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Mesoblast jumps on key drug's quarterly sales surge** ASX-listed Mesoblast MSB.AX pares early surge to trade 8.1% higher at A$2.8 by midday in Sydney, still among the top ASX200 .AXJO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nL6N3VO03H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","MSB.AU","BK7508"],"gpt_icon":0},{"id":"2573388489","title":"BRIEF-Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2573388489","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573388489?lang=en_us&edition=fundamental","pubTime":"2025-10-07 09:36","pubTimestamp":1759800984,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For QuarterOct 7 (Reuters) - Mesoblast Ltd MSB.AX:GROSS REVENUE OF $21.9 MILLION ON RYONCIL SALES FOR QUARTERFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VN1UA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","MSB.AU","BK7508"],"gpt_icon":0},{"id":"2573126984","title":"Ryoncil® Revenues Increase 66% in Second Quarter Post Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2573126984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573126984?lang=en_us&edition=fundamental","pubTime":"2025-10-07 07:24","pubTimestamp":1759793094,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA5JPG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","MSB.AU"],"gpt_icon":0},{"id":"1175565657","title":"Stock Track | Mesoblast Soars 11.20% as Ryoncil Sales Drive $21.9 Million Quarterly Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1175565657","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175565657?lang=en_us&edition=fundamental","pubTime":"2025-10-07 07:02","pubTimestamp":1759791767,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) shares skyrocketed 11.20% in Tuesday's trading session, following the company's announcement of strong quarterly revenue driven by sales of its flagship product, Ryoncil. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1141904464","title":"Stock Track | Mesoblast Soars 11.20% as Quarterly Ryoncil Sales Generate $21.9 Million Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1141904464","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141904464?lang=en_us&edition=fundamental","pubTime":"2025-10-07 07:02","pubTimestamp":1759791762,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) shares are soaring in Tuesday's trading session, surging by 11.20% following the company's announcement of strong quarterly sales figures for its flagship product, Ryoncil....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"2573981198","title":"Mesoblast Ltd -  Gross Revenue of $21.9 Mln on Ryoncil Sales for Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2573981198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573981198?lang=en_us&edition=fundamental","pubTime":"2025-10-07 06:45","pubTimestamp":1759790733,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nFWN3VN1UA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2573459106","title":"Why Mesoblast (ASX:MSB) Is Up 15.0% After Securing US Medicare J-Code for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2573459106","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573459106?lang=en_us&edition=fundamental","pubTime":"2025-10-06 04:12","pubTimestamp":1759695151,"startTime":"0","endTime":"0","summary":"Mesoblast Limited announced that the permanent Medicare and Medicaid J-Code J3402 for Ryoncil® became active for billing and reimbursement on October 1, 2025, creating a standardized pathway for US healthcare providers.\nThis formal CMS recognition is expected to streamline access and reimbursement, potentially broadening patient reach for the only FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease.\nWe'll now explore how this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-150-after-securing-us-medicare-j","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-150-after-securing-us-medicare-j","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","MSB.AU","BK7067","MSB","BK4006","BK7501"],"gpt_icon":0},{"id":"2572639689","title":"Mesoblast (ASX:MSB): Assessing Valuation After Ryoncil Wins Permanent U.S. J-Code for Reimbursement","url":"https://stock-news.laohu8.com/highlight/detail?id=2572639689","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572639689?lang=en_us&edition=fundamental","pubTime":"2025-10-04 02:32","pubTimestamp":1759516333,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) drew investor attention after announcing that its product, Ryoncil, was granted a permanent J-Code by the U.S. Medicare & Medicaid Services for billing and reimbursement beginning in October 2025.\nSee our latest analysis for Mesoblast.\nMomentum around Mesoblast has picked up following the news about Ryoncil’s new billing code and its designation as a U.S.-origin product, making reimbursement and commercial pathways much clearer for the company. While its short-term share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-assessing-valuation-after-ryoncil-wins-perm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-assessing-valuation-after-ryoncil-wins-perm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7501","MSB","DCF","BK7508","MSB.AU","BK4006"],"gpt_icon":0},{"id":"2572555996","title":"Weekly Wrap: Will the ASX 200 Break Records? Investors Hope for Continued Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2572555996","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572555996?lang=en_us&edition=fundamental","pubTime":"2025-10-03 22:06","pubTimestamp":1759500367,"startTime":"0","endTime":"0","summary":"The Australian share market overcame a poor start to rise and salutes the end of the week on Friday, well within reach of record highs.A broad rally in sectors such as healthcare, IT, consumer discretionary and real estate stocks helped to overcome weakness in energy and utilities, helping the ASX 200 to rise by 0.5% or 41.5 points to close at 8987.4 points.That is not far off the record close of 9019.2 points set in August – a level that could be eclipsed in the coming week if the positive trend continues.There is a chance of that as investors continue to see signs of profit growth locally and offshore, with the chance of interest rate cuts coming down the track.Although there is plenty to worry about as well, with the United States once again “enjoying” another public service shutdown of unknown duration and no shortage of doomsayers warning of an AI investment overshoot and rising unemployment.It was a good day too for shareholders in Mesoblast  as the stock added 8.7% t","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/featured-1759499950581.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/featured-1759499950581.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/will-the-asx-200-break-records-investors-hope-for-continued-momentum/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/will-the-asx-200-break-records-investors-hope-for-continued-momentum/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["STO.AU","BK7016","BK7508","BK7094","BK7142","AGL.AU","RMD.AU","WDS.AU","BK7007","TLS.AU","BK7143","BK7503","RHC.AU","ISBC","APE.AU","BK7506","CSL.AU","EVN.AU","BK7507","BK7113","HOPE","MSB.AU","PME.AU","RMS.AU","BK7067","360.AU","BK7501","DGT.AU","BK7061","BK7511","BK4211","BK7042","APX.AU","BK7166","XYZ.AU","BK7136","BK7104","NST.AU","BK7158"],"gpt_icon":0},{"id":"1162680072","title":"Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Secures US Medicare Billing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1162680072","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162680072?lang=en_us&edition=fundamental","pubTime":"2025-10-03 09:40","pubTimestamp":1759455617,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) shares skyrocketed 16.93% in Friday's trading session, reaching their highest level since February 13. The surge came after the company announced that its key drug, Ryoncil,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1103730648","title":"Stock Track | Mesoblast Soars 16.93% as Key Drug Ryoncil Receives US Medicare Billing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1103730648","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103730648?lang=en_us&edition=fundamental","pubTime":"2025-10-03 09:40","pubTimestamp":1759455614,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd (MSB.AU) shares surged 16.93% in intraday trading, reaching A$2.970, their highest level since February 13. The biotech firm's stock price jump comes on the heels of a significant...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":146,"code":"91000000","status":"200"}]}}